The Potential Cardiotoxicity of Immune Checkpoint Inhibitors

The use of immune checkpoint inhibitors (ICIs) as a mono- or adjuvant oncologic treatment is rapidly expanding to most fields of cancer. Alongside their efficacy, ICIs carry the risk of immune-related adverse events (irAEs) arising from misguided immune-mediated response to normal tissues. In the ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardi Agmon, Inbar, Itzhaki Ben Zadok, Osnat, Kornowski, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836470/
https://www.ncbi.nlm.nih.gov/pubmed/35160316
http://dx.doi.org/10.3390/jcm11030865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836470/
https://www.ncbi.nlm.nih.gov/pubmed/35160316
http://dx.doi.org/10.3390/jcm11030865

Ejemplares similares